Swiss National Bank
PVLA

Swiss National Bank’s Palvella Therapeutics PVLA Stock Holding History

Swiss National Bank’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
19,400
+5,200
+37% +$542K ﹤0.01% 1755
2025
Q4 		$1.49M Buy
+14,200
New +$1.21M ﹤0.01% 1999

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Swiss National Bank's PVLA Position: Q1 2026 in Review

Swiss National Bank increased its Palvella Therapeutics (PVLA) stake by 37% in Q1 2026, buying an estimated $542K and bringing the position to 19,400 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Swiss National Bank first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Swiss National Bank held 19,400 shares of Palvella Therapeutics worth $2.42M as of Q1 2026.
  • Swiss National Bank bought 5,200 Palvella Therapeutics shares in Q1 2026, an estimated $542K.
  • Palvella Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1755 holding.
  • Swiss National Bank first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.